Nutrineal Pd4 (Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serin)

The amino acids are delivered directly into the peritoneal cavity, where they are absorbed into the bloodstream. Once in circulation, they serve as building blocks for protein synthesis, support gluconeogenesis, and help maintain nitrogen balance, thereby aiding tissue repair and metabolic stability.

The dose of Nutrineal Pd4 is individualized. The prescribing clinician determines the amount based on the patient’s weight, clinical condition, renal and hepatic function, and overall nutritional goals. No fixed regimen is provided in the product information.

Safety data for Nutrineal Pd4 in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Nutrineal Pd4, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Nutrineal Pd4 offers a comprehensive amino‑acid profile designed for intraperitoneal delivery, whereas many alternatives are formulated for intravenous use only. Its specific blend may provide more balanced essential amino‑acid provision for certain clinical scenarios, but selection should be based on individual patient needs and institutional protocols.

Nutrineal Pd4 should be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the product. Before administration, allow the solution to reach room temperature if required by the clinical protocol.

Nutrineal Pd4 is administered via the intraperitoneal route, typically as part of a sterile parenteral nutrition regimen. The solution is infused under aseptic conditions, and the rate is adjusted according to the patient’s metabolic requirements and clinical response.

Serious risks include severe allergic reactions (anaphylaxis), acute renal impairment from nitrogen overload, metabolic acidosis, and circulatory overload due to hyperosmolarity. Patients should be closely monitored for signs of these events, especially during the initial infusion period.

Nutrineal Pd4 is contraindicated in patients with known hypersensitivity to any of its amino‑acid components, severe renal failure where nitrogen excretion is compromised, and in those with uncontrolled metabolic disorders that could be exacerbated by amino‑acid infusion.